ASTRANA HEALTH INC
ASTHNASDAQTrading Snapshot
- Day Range
- $35.33 β $36.08
- 52-Week Range
- $18.08 β $51.60
- Volume
- $2.45B
- Avg Volume
- $1.94B
- Shares Outstanding
- 49.6M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.18B
- Last Q Revenue
- $973M
- P/E Ratio
- 42.6
- P/S Ratio
- 0.4x
- EPS (TTM)
- $0.82
- Dividend Yield
- 0.11%
- Dilution (1yr)
- +3.3%
Why Investors Own ASTH
- βHigh-growth profile β revenue up +18.8% YoY with expanding US Equity exposure.
- βHealthy economics β 76% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ASTRANA HEALTH INC
ASTHAbout ASTRANA HEALTH INC
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverageβsuch as private plans, Medicare, Medicaid, and HMOsβbut also extends care to uninsured individuals.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc. - ASTH
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. (βAstranaβ or the βCompanyβ) (NASDAQ: ASTH). Such investors are advised to contact Daniell

ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ASTH--ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law.

PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach
SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of individuals affiliated with Astrana Health, Inc.'s subsidiary, Astrana Health Ma

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Astrana Health, Inc.- ASTH
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. ("Astrana" or the "Company") (NASDAQ: ASTH).

Lowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Laws
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.

Astrana Health: 81% Full-Risk And Profitable
Astrana Health is rated a buy, trading at a 46% discount to peers despite sector-wide reserve releases clarifying earnings quality concerns. ASTH's Care Enablement platform drove G&A costs from 7.75% to 5.57% of revenue,